CDK4/6 inhibitors have excellent efficacy in prolonging progression-free survival (PFS) and overall survival (OS), and have become a key option for HR+/HER2- breast cancer first-line and adjuvant treatment. This evidence concerns the gene CDK4 and breast cancer.